» Articles » PMID: 28900428

C-Reactive Protein Binds to Cholesterol Crystals and Co-Localizes with the Terminal Complement Complex in Human Atherosclerotic Plaques

Overview
Journal Front Immunol
Date 2017 Sep 14
PMID 28900428
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Inflammation is a part of the initial process leading to atherosclerosis and cholesterol crystals (CC), found in atherosclerotic plaques, which are known to induce complement activation. The pentraxins C-reactive protein (CRP), long pentraxin 3 (PTX3), and serum amyloid P component (SAP) are serum proteins associated with increased risk of cardiovascular events and these proteins have been shown to interact with the complement system. Whether the pentraxins binds to CC and mediate downstream complement-dependent inflammatory processes remains unknown. Binding of CRP, PTX3, and SAP to CC was investigated by flow cytometry and fluorescence microscopy. CRP, PTX3, and SAP bound to CC in a concentration-dependent manner. CRP and PTX3 interacted with the complement pattern recognition molecule C1q on CC by increasing the binding of both purified C1q and C1q in plasma. However, CRP was the strongest mediator of C1q binding and also the pentraxin that most potently elevated C1q-mediated complement activation. In a phagocytic assay using whole blood, we confirmed that phagocytosis of CC is complement dependent and initiated by C1q-mediated activation. The pathophysiological relevance of the observations was examined in human atherosclerotic plaques. CRP, PTX3, and SAP were all found in atherosclerotic plaques and were located mainly in the cholesterol-rich necrotic core, but co-localization with the terminal C5b-9 complement complex was only found for CRP. In conclusion, this study identifies CRP as a strong C1q recruiter and complement facilitator on CC, which may be highly relevant for the development of atherosclerosis.

Citing Articles

The complement system in lipid-mediated pathologies.

Alic L, Dendinovic K, Papac-Milicevic N Front Immunol. 2024; 15:1511886.

PMID: 39635529 PMC: 11614835. DOI: 10.3389/fimmu.2024.1511886.


Chronic low-grade inflammation in patients with systemic sclerosis is associated with increased risk for arteriosclerotic cardiovascular disease.

Heilmeier U, Feldmann D, Leynes A, Seng M, Jandova I, Keute M Front Med (Lausanne). 2024; 11:1446268.

PMID: 39564499 PMC: 11573558. DOI: 10.3389/fmed.2024.1446268.


C-Reactive Protein in Atherosclerosis-More than a Biomarker, but not Just a Culprit.

Kirkgoz K Rev Cardiovasc Med. 2024; 24(10):297.

PMID: 39077585 PMC: 11262456. DOI: 10.31083/j.rcm2410297.


C-reactive protein: structure, function, regulation, and role in clinical diseases.

Zhou H, Tang Y, Xu T, Cheng B Front Immunol. 2024; 15:1425168.

PMID: 38947332 PMC: 11211361. DOI: 10.3389/fimmu.2024.1425168.


The relationship between complement C1q and coronary plaque vulnerability based on optical coherence tomography analysis.

Wang Y, Zheng J, Li Q, Ma Y, Liu C, Deng J Sci Rep. 2024; 14(1):9477.

PMID: 38658599 PMC: 11043360. DOI: 10.1038/s41598-024-60128-0.


References
1.
Doni A, Peri G, Chieppa M, Allavena P, Pasqualini F, Vago L . Production of the soluble pattern recognition receptor PTX3 by myeloid, but not plasmacytoid, dendritic cells. Eur J Immunol. 2003; 33(10):2886-93. DOI: 10.1002/eji.200324390. View

2.
de Beer F, Hind C, Fox K, Allan R, Maseri A, Pepys M . Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J. 1982; 47(3):239-43. PMC: 481128. DOI: 10.1136/hrt.47.3.239. View

3.
Haverkate F, Thompson S, Pyke S, Gallimore J, Pepys M . Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997; 349(9050):462-6. DOI: 10.1016/s0140-6736(96)07591-5. View

4.
Dubin R, Li Y, Ix J, Shlipak M, Whooley M, Peralta C . Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study. Am Heart J. 2012; 163(2):274-9. PMC: 3273726. DOI: 10.1016/j.ahj.2011.11.007. View

5.
Gout E, Moriscot C, Doni A, Dumestre-Perard C, Lacroix M, Perard J . M-ficolin interacts with the long pentraxin PTX3: a novel case of cross-talk between soluble pattern-recognition molecules. J Immunol. 2011; 186(10):5815-22. DOI: 10.4049/jimmunol.1100180. View